SYNLOGIC, INC. Payments to Acquire Available-for-sale Securities
SYNLOGIC, INC. (SYBX) reported Payments to Acquire Available-for-sale Securities of $114.98 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-08-09
- SYNLOGIC, INC. payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $40.02M, a 158.02% increase year-over-year.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $74.96M, a 523.71% increase year-over-year.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $28.58M.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was -$4.67M.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for fiscal 2017 was $51.44M, a 50.12% decline from fiscal 2016.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for fiscal 2016 was $103.11M.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for fiscal 2015 was $0.00.
- SYNLOGIC, INC. payments to acquire available-for-sale securities for fiscal 2014 was $0.00.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-06-30 | $40.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $114.98M 10-Q · filed 2018-08-09 | $143.56M derived: sum of 3 quarters · filed 2018-08-09 | $138.89M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | $74.96M 10-Q · filed 2018-05-15 | $103.55M derived: sum of 2 quarters · filed 2018-05-15 | $98.87M derived: sum of 3 quarters · filed 2018-05-15 | $114.38M derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-12-31 | $28.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $23.91M derived: sum of 2 quarters · filed 2018-03-20 | $39.42M derived: sum of 3 quarters · filed 2018-03-20 | $51.44M 10-K · filed 2018-03-20 |
| 2017-09-30 | -$4.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $10.84M derived: sum of 2 quarters · filed 2017-11-13 | $22.86M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $15.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $27.53M 10-Q · filed 2017-08-04 | ||
| 2017-03-31 | $12.02M 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $103.11M 10-K · filed 2017-03-15 | |||
| 2016-06-30 | $23.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $50.85M 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | $27.72M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |